AR106295A1 - Tetrahidropiranilsulfonas sustituidas con pirazolilo - Google Patents
Tetrahidropiranilsulfonas sustituidas con pirazoliloInfo
- Publication number
- AR106295A1 AR106295A1 ARP160103076A ARP160103076A AR106295A1 AR 106295 A1 AR106295 A1 AR 106295A1 AR P160103076 A ARP160103076 A AR P160103076A AR P160103076 A ARP160103076 A AR P160103076A AR 106295 A1 AR106295 A1 AR 106295A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- membered heterocyclyl
- group
- heteroaryl
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 54
- 125000000623 heterocyclic group Chemical group 0.000 abstract 13
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 101150020251 NR13 gene Proteins 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- -1 S(=O)2CH3 Chemical group 0.000 abstract 2
- 101100495923 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr2 gene Proteins 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- LPEJBHOGJFUPOR-UHFFFAOYSA-N 2-(oxan-2-ylsulfonyl)oxane Chemical class C1CCCOC1S(=O)(=O)C1CCCCO1 LPEJBHOGJFUPOR-UHFFFAOYSA-N 0.000 abstract 1
- GZFPWZQBIISAPE-UHFFFAOYSA-N COCCN1N=C(C=C1C1OCCC(C1)(S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C)C(F)(F)F Chemical compound COCCN1N=C(C=C1C1OCCC(C1)(S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C)C(F)(F)F GZFPWZQBIISAPE-UHFFFAOYSA-N 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 abstract 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a tetrahidropiranilsulfonas sustituidas con pirazolilo como bloqueadores de los canales de calcio dependientes de voltaje, a composiciones farmacéuticas que contienen estos compuestos y también a estos compuestos para utilizar en el tratamiento y/o profilaxis del dolor y de otras enfermedades y/o trastornos. Reivindicación 1: Un compuesto de fórmula general (1), donde R¹ se selecciona del grupo que consiste en H o alquilo C₁₋₆; R² se selecciona del grupo que consiste en H o alquilo C₁₋₆; R³ representa L-R³ᵃ, donde L es un enlace o CH₂ y R³ᵃ se selecciona del grupo que consiste en alquilo C₁₋₆ sustituido, cicloalquilo C₃₋₆ o heterociclilo de 3 a 7 miembros, donde dicho alquilo C₁₋₆ sustituido está sustituido con uno o dos sustituyentes seleccionados independientemente del grupo que consiste en OH, OCH₃, S(=O)₂CH₃, N(CH₃)₂, C(=O)NH₂, C(=O)NH(CH₃) y C(=O)N(CH₃)₂; donde dicho cicloalquilo C₃₋₆ y dicho heterociclilo de 3 a 7 miembros están sin sustituir o sustituidos con uno o dos sustituyentes seleccionados independientemente del grupo que consiste en OH, OCH₃, =O, S(=O)₂CH₃, NH₂, NH(CH₃), N(CH₃)₂, C(=O)OH, C(=O)NH₂, C(=O)NH(CH₃) y C(=O)N(CH₃)₂; y donde dicho heterociclilo de 3 a 7 miembros contiene uno o dos heteroátomos o grupos de heteroátomos seleccionados independientemente del grupo que consiste en O, NH, N(CH₃), S(=O) y S(=O)₂; R⁴ representa L-R⁵, donde L es un enlace, CH₂, C(CH₃)₂, O ó S(=O)₂ y R⁵ se selecciona del grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₆ o heterociclilo de 3 a 7 miembros, donde dicho heterociclilo de 3 a 7 miembros se caracteriza porque contiene un heteroátomo o grupo de heteroátomos, seleccionados entre O, NH, N(CH₃), S(=O) y S(=O)₂; donde dicho alquilo C₁₋₆ está sin sustituir o sustituido con uno o dos o tres o cuatro sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, CN, OH, OCH₃, OCFH₂, OCHF₂, OCF₃, S(=O)₂CH₃, S(=O)₂CHF₂, S(=O)₂CF₃, S(=O)₂CH(CH₃)₂, S(=O)₂(c-propilo), NH₂, NH(CH₃), N(CH₃)₂, C(=O)NH₂, C(=O)NH(CH₃) y C(=O)N(CH₃)₂; y donde dicho cicloalquilo C₃₋₆ o dicho heterociclilo de 3 a 7 miembros está sin sustituir o sustituido con uno o dos o tres o cuatro sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, CN, CH₃, CFH₂, CHF₂, CF₃, =O, OH, OCH₃, CH₂OH, CH₂OCH₃, OCFH₂, OCHF₂, OCF₃, S(=O)₂CH₃, S(=O)₂CHF₂, S(=O)₂CF₃, S(=O)₂CH(CH₃)₂, S(=O)₂(c-propilo), NH₂, NH(CH₃), N(CH₃)₂, C(=O)NH₂, C(=O)NH(CH₃) y C(=O)N(CH₃)₂; Ar¹ representa arilo o heteroarilo, donde dicho arilo o dicho heteroarilo está sustituido con cero o uno o dos o tres sustituyentes R⁷, donde cada R⁷ se selecciona independientemente del grupo que consiste en F; Cl; Br; I; NO₂; CN; alquilo C₁₋₆; CF₃; CF₂H; CFH₂; CF₂Cl; CFCl₂; C(O)-H; C(O)-alquilo C₁₋₆; C(O)-OH; C(O)-O-alquilo C₁₋₆; C(O)-N(H)(OH); C(O)-NH₂; C(O)-N(H)(alquilo C₁₋₆); C(O)-N(alquilo C₁₋₆)₂; C(=N-OH)-H; C(=N-OH)-alquilo C₁₋₆; C(=N-O-alquil C₁₋₆)-H; C(=N-O-alquil C₁₋₆)-alquilo C₁₋₆; OH; OCF₃; OCF₂H; OCFH₂; OCF₂Cl; OCFCl₂; O-alquilo C₁₋₆; O-C(O)-alquilo C₁₋₆; O-C(O)-O-alquilo C₁₋₆; O-(CO)-N(H)(alquilo C₁₋₆); O-C(O)-N(alquilo C₁₋₆)₂; O-S(O)₂-alquilo C₁₋₆; O-S(O)₂-OH; O-S(O)₂-O-alquilo C₁₋₆; O-S(O)₂-NH₂; O-S(O)₂-N(H)(alquilo C₁₋₆); O-S(O)₂-N(alquilo C₁₋₆)₂; NH₂; N(H)(alquilo C₁₋₆); N(alquilo C₁₋₆)₂; N(H)-C(O)-alquilo C₁₋₆; N(H)-C(O)-O-alquilo C₁₋₆; N(H)-C(O)-NH₂; N(H)-C(O)-N(H)(alquilo C₁₋₆); N(H)-C(O)-N(alquilo C₁₋₆)₂; N(alquil C₁₋₆)-C(O)-alquilo C₁₋₆; N(alquil C₁₋₆)-C(O)-O-alquilo C₁₋₆; N(alquil C₁₋₆)-C(O)-NH₂; N(alquil C₁₋₆)-C(O)-N(H)(alquilo C₁₋₆); N(alquil C₁₋₆)-C(O)-N(alquilo C₁₋₆)₂; N(H)-S(O)₂OH; N(H)-S(O)₂-alquilo C₁₋₆; N(H)-S(O)₂-O-alquilo C₁₋₆; N(H)-S(O)₂-NH₂; N(H)-S(O)₂-N(H)(alquilo C₁₋₆); N(H)-S(O)₂N(alquilo C₁₋₆)₂; N(alquil C₁₋₆)-S(O)₂-OH; N(alquil C₁₋₆)-S(O)₂-alquilo C₁₋₆; N(alquil C₁₋₆)-S(O)₂-O-alquilo C₁₋₆; N(alquil C₁₋₆)-S(O)₂-NH₂; N(alquil C₁₋₆)-S(O)₂-N(H)(alquilo C₁₋₆); N(alquil C₁₋₆)-S(O)₂-N(alquilo C₁₋₆)₂; SH; SCF₃; SCF₂H; SCFH₂; SCF₂Cl; SCFCl₂; S-alquilo C₁₋₆; S(O)-alquilo C₁₋₆; S(O)₂-alquilo C₁₋₆; S(O)₂-OH; S(O)₂-O-alquilo C₁₋₆; S(O)₂-NH₂; S(O)₂-N(H)(alquilo C₁₋₆); S(O)₂-N(alquilo C₁₋₆)₂; cicloalquilo C₃₋₆; heterociclilo de 3 a 7 miembros; arilo; heteroarilo; O-cicloalquilo C₃₋₆; O-(heterociclilo de 3 a 7 miembros); O-arilo; O-heteroarilo; N(H)-cicloalquilo C₃₋₆; N(H)-(heterociclilo de 3 a 7 miembros); N(H)-arilo; N(H)-heteroarilo; N(alquil C₁₋₆)-cicloalquilo C₃₋₆; N(alquil C₁₋₆)-(heterociclilo de 3 a 7 miembros); N(alquil C₁₋₆)-arilo; N(alquil C₁₋₆)-heteroarilo; C(O)-cicloalquilo C₃₋₆; C(O)-(heterociclilo de 3 a 7 miembros); C(O)-arilo; C(O)-heteroarilo; S(O)₂-cicloalquilo C₃₋₆; S(O)₂-(heterociclilo de 3 a 7 miembros); S(O)₂-arilo; S(O)₂-heteroarilo; S(O)(NR¹³)-cicloalquilo C₃₋₆; S(O)(NR¹³)-(heterociclilo de 3 a 7 miembros); S(O)(NR¹³)-arilo y S(O)(NR¹³)-heteroarilo, donde R¹³ representa H o alquilo C₁₋₆; con la condición de que el compuesto de fórmula general (1) no sea 1-(2-metoxietil)-5-(4-metil-4-((3-(trifluorometil)fenil)sulfonil)tetrahidro-2H-piran-2-il)-3-(trifluorometil)-1H-pirazol, opcionalmente en forma de un estereoisómero único o una mezcla de estereoisómeros, en forma del compuesto libre y/o una sal fisiológicamente aceptable y/o un solvato fisiológicamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15002880 | 2015-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106295A1 true AR106295A1 (es) | 2018-01-03 |
Family
ID=54293015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103076A AR106295A1 (es) | 2015-10-08 | 2016-10-07 | Tetrahidropiranilsulfonas sustituidas con pirazolilo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10100041B2 (es) |
| JP (1) | JP2018530569A (es) |
| CN (1) | CN108473480A (es) |
| AR (1) | AR106295A1 (es) |
| AU (1) | AU2016336777A1 (es) |
| BR (1) | BR112018007004A2 (es) |
| CA (1) | CA3001949A1 (es) |
| HK (1) | HK1258461A1 (es) |
| MX (1) | MX2018004217A (es) |
| TW (1) | TW201726128A (es) |
| WO (1) | WO2017059966A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA032638B1 (ru) | 2014-04-14 | 2019-06-28 | Грюненталь Гмбх | Арилзамещенные гетероциклилсульфоны |
| US9879000B2 (en) | 2014-04-14 | 2018-01-30 | Grünenthal GmbH | Heteroaryl substituted heterocyclyl sulfones |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| EP4253380A3 (en) * | 2019-10-18 | 2023-11-15 | FMC Corporation | Methods for the preparation of 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylic acid |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007125398A2 (en) * | 2006-04-27 | 2007-11-08 | Pfizer Japan Inc. | : sulfonamide compounds as antagonists of the n-type calcium channel |
| CA2687764A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| NZ598269A (en) | 2009-09-18 | 2014-12-24 | Zalicus Pharmaceuticals Ltd | Aryl sulphone derivatives as calcium channel blockers |
| BR112015003393A2 (pt) * | 2012-08-16 | 2017-07-04 | Janssen Pharmaceutica Nv | pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n |
| PE20151140A1 (es) * | 2012-08-16 | 2015-08-07 | Janssen Pharmaceutica Nv | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n |
| TW201416348A (zh) * | 2012-08-29 | 2014-05-01 | Gruenenthal Chemie | 以氟甲基取代之吡咯甲醯胺 |
| EA032638B1 (ru) * | 2014-04-14 | 2019-06-28 | Грюненталь Гмбх | Арилзамещенные гетероциклилсульфоны |
| US9879000B2 (en) * | 2014-04-14 | 2018-01-30 | Grünenthal GmbH | Heteroaryl substituted heterocyclyl sulfones |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
-
2016
- 2016-10-06 TW TW105132386A patent/TW201726128A/zh unknown
- 2016-10-07 CA CA3001949A patent/CA3001949A1/en not_active Abandoned
- 2016-10-07 HK HK19100766.1A patent/HK1258461A1/zh unknown
- 2016-10-07 US US15/288,009 patent/US10100041B2/en not_active Expired - Fee Related
- 2016-10-07 CN CN201680062218.7A patent/CN108473480A/zh active Pending
- 2016-10-07 AR ARP160103076A patent/AR106295A1/es unknown
- 2016-10-07 JP JP2018517899A patent/JP2018530569A/ja not_active Withdrawn
- 2016-10-07 WO PCT/EP2016/025108 patent/WO2017059966A1/en not_active Ceased
- 2016-10-07 MX MX2018004217A patent/MX2018004217A/es unknown
- 2016-10-07 BR BR112018007004A patent/BR112018007004A2/pt not_active Application Discontinuation
- 2016-10-07 AU AU2016336777A patent/AU2016336777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016336777A1 (en) | 2018-04-12 |
| US10100041B2 (en) | 2018-10-16 |
| JP2018530569A (ja) | 2018-10-18 |
| MX2018004217A (es) | 2018-06-13 |
| WO2017059966A1 (en) | 2017-04-13 |
| HK1258461A1 (zh) | 2019-11-15 |
| TW201726128A (zh) | 2017-08-01 |
| CA3001949A1 (en) | 2017-04-13 |
| US20170101398A1 (en) | 2017-04-13 |
| CN108473480A (zh) | 2018-08-31 |
| BR112018007004A2 (pt) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106296A1 (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo | |
| AR100073A1 (es) | Sulfonas heterocíclicas sustituidas con heteroarilos | |
| CL2022000619A1 (es) | Oxinitruro de piridina, método para su preparación y uso de este | |
| MX418596B (es) | Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados | |
| AR097325A1 (es) | Pirroles anillados | |
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| AR108906A1 (es) | Heterociclos de biarilmetilo | |
| AR093810A2 (es) | Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa ak, sus usos, composiciones, kits y formas de dosificacion | |
| PE20220569A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| PY1923494A (es) | Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida | |
| EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| AR104714A1 (es) | Compuestos depsipeptídicos como antihelmínticos | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR092279A1 (es) | Pirrol carboxamidas fluorometilo sustituidas | |
| EA201891379A1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения | |
| AR101196A1 (es) | Compuestos de pirimidina sustituidos | |
| EA201590022A1 (ru) | Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| AR118729A1 (es) | Inhibidor selectivo de la jak1 quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |